Microsoft, Alphabet, CoStar and more

Check out the companies making headlines in midday trading. Microsoft — Shares jumped 2.5% as investors cheered the Xbox maker's fiscal first-quarter results released Tuesday. Microsoft posted almost 13% year-over-year revenue growth, and its Azure cloud segment saw revenue gain 29% for the quarter. The Windows software maker also...

Read more...

GM, Honda scrap plans to co-develop ‘affordable’ sub-$30,000 EVs

The 2024 Honda Prologue is one of two EVs being made by General Motors for the Japanese automaker, utilizing its Ultium battery technologies.HondaDETROIT – General Motors and Honda Motor have canceled plans to jointly develop affordable electric vehicles as they face slower-than-expected demand and changing market conditions.The unwinding of...

Read more...

Meta to report third-quarter earnings after the bell

Mark Zuckerberg, CEO of Meta, attends a U.S. Senate bipartisan Artificial Intelligence Insight Forum at the U.S. Capitol in Washington, D.C., Sept. 13, 2023.Stefani Reynolds | AFP | Getty ImagesMeta is set to report third-quarter earnings after the bell Wednesday.Here are the key numbers Wall Street will be watching:Earnings: $3.63...

Read more...

JetBlue to offer Dublin, Edinburgh flights starting next year

JetBlue Airways aircraft are pictured at departure gates at John F. Kennedy International Airport in New York on June 15, 2013.Fred Prouser | ReutersJetBlue Airways plans to begin flights to Dublin and Edinburgh from the U.S. as part of the carrier's trans-Atlantic expansion.Tickets for the newly offered destinations went...

Read more...

IMAX earnings Q3 2023

Christopher Nolan's 'Oppenheimer' movie billboard is seen in Katowice, Poland on July 20, 2023.Beata Zawrzel | Nurphoto | Getty ImagesIMAX on Wednesday posted third quarter earnings showing its second highest-grossing quarter ever at the global box office, led by Universal's "Oppenheimer."Shares slipped about 4% in early trading, however.Here's how...

Read more...

GSK RSV vaccine shows potential to protect adults 50 to 59

A vaccine from GlaxoSmithKline showed the potential to protect adults ages 50 to 59 from respiratory syncytial virus in a late-stage clinical trial, the company said Wednesday.The initial trial results suggest that GSK's shot, known as Arexvy, could help protect a wider population from RSV, a disease that causes...

Read more...